Chemical Nameosimertinib
Dosage FormTablet (oral; 40 mg, 80 mg)
Drug ClassKinase inhibitors
Approval Year2015


  • The first line treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 L858R mutations.
  • The treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive NSCLC whose disease has progressed on or after epidermal growth factor receptor TKI therapy.
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tagrisso (osimertinib) Prescribing Information2019AstraZeneca Pharmaceutica, Wilmington, DE